Cell Proliferation Assays

Info in Brief

Free choice setup

The free choice setup, allows the client to test any number of compounds against any number of cell lines. Screening can be performed in single concentration mode for high-throughput projects or IC50 mode (8 concentrations in duplicates).

InfoSheet: Cell Proliferation Assay

ProLiFiler setup

Testing is performed on a panel of 120 human tumor cell lines with IC50 value determination (8 concentrations, duplicates).

Timelines: We are performing continuous screening and start over every 6 weeks. 

InfoSheet_ProLiFiler

Drug Combination Testing

ProQinase tests drug combination with either one-sided or two-sided approaches in either low or high-throughput setups. Drug Combination Testing is available for both, cell proliferation assay on a custom panel of cell lines or the ProLiFiler comprising testing of 120 cell lines.

Poster: Analysis of the combinatorial anti-proliferative effect of panRAF inhibitor AZ-628 and MEK1 inhibitor Selumetinib on a large panel of tumor cell lines.

Info_Sheet: Drug Combination Testing

Cpd Exposure

72 h

Readout

CellTiter-Glo® Luminescent

Testing Formats

IC50 (8 semi-log dilutions in duplicate)

Cpd Submission

Solved or as pre-weighed powder

Reference Cpd

included

Report

Comprehensive evaluation of data including raw data for own analysis
Sample report will be provided upon request

Guidelines for Cpd Submission

EXCEL-FILE

Reference compounds tested in the Cell Proliferation Assay

Tozasertib (MK-0457, VX-680), GSK2981278, Doxorubicin (Doxil, Adriablastin), Paclitaxel (Taxol A, Abraxane), Bortezomib (Velcade), Staurosporine, PHA665752, Sunitinib (Sutent), Everolimus (Afinitor), VE-821, Cisplatin (platamin, neoplatin), Selumetinib (AZD6244, ARRY-142886), AZ628; UNC-2025, R-428, Actinomycin D (Dactinomycin), Mertansine (DM1, Maytansinoid), Monomethylauristatin E (MMAE; SGD-1010), Trametinib (GSK1120212), Crizotinib (Xalkori), A1210477, S68345, Navitoclax (ABT-263), Panobinostat (LBH589,  NVP-LBH589)